Nyrada, Inc. · ASX:NYR
Nyrada — Meet the CEO, Life Sciences Edition (March 2022)
19 slides from Nyrada's conference presentation, Mar 2, 2022
Slide 1: Meet the CEO, Life Sciences Edition
For personal use only ‘Meet the CEO, Life Sciences Edition’ James Bonnar, Nyrada CEO 3 March 2022│Sydney NSW NYRADA INC (ASX:NYR) Authorised by Mr. John Moore, Non-Executive 1 Chairman, on behalf of the Board. INVESTOR PRESENTATION
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer For personal use only This presentation has been prepared by Nyrada Inc (NYR or the Company). It should Although the Company believes that the expectations reflected in the forward-looking not be considered as an offer or invitation to subscribe for, or purchase any sha
Slide 3: Company Overview
Company Overview For personal use only • Two lead drug development programs with significant therapeutic and commercial potential: • Cholesterol-Lowering Program • Brain Injury Program • Collaborations with world leading institutions, Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney •
Slide 4: Nyrada Board of Directors
Nyrada Board of Directors For personal use only Mr John Moore Dr Ian Dixon Christopher Cox Mr Peter Marks Mr Marcus Frampton Dr Rüdiger Weseloh Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Chairman Director Director Director Director Director • Nyrada operates
Slide 5: Vision & Strategy
Vision & Strategy For personal use only • To improve lives and offer hope through innovation • Deliver novel treatments for diseases where: • There is unmet clinical need; or • Current treatments are suboptimal Our strategy is to advance highly optimised drug candidates towards a key value inflectio
Slide 6: Cholesterol-Lowering Program
For personal use only Cholesterol-Lowering Program ASX:NYR NYRADA INC (ASX:NYR) 6 INVESTOR PRESENTATION
Slide 7: High LDL Cholesterol and Cardiovascular Disease (CVD)
High LDL Cholesterol and Cardiovascular Disease (CVD) Problem and key statistics For personal use only High LDL cholesterol CVD responsible for Healthcare costs for CVD a leading cause of CVD 1 in 4 deaths ~US$363B/year (US)1 Statins are suboptimal for 70% of patients and often poorly tolerated 62M
Slide 8: Nyrada's Cholesterol-Lowering Program
Nyrada’s Cholesterol-Lowering Program For personal use only • We are developing an oral PCSK9 inhibitor drug (taken as a pill) for the treatment of high LDL (bad) cholesterol levels in patients at risk of cardiovascular disease • Nyrada’s drug would replace expensive and inconvenient injectable PCSK
Slide 9: Program Milestones
Program Milestones For personal use only Medicinal chemistry program reveals new NYX-PCSK9i potent drug mechanism of action NYX-PCSK9i shows candidates confirmed following 57% reduction in total further exploratory cholesterol1 analysis1 July Jan June July Dec CY 2020 2021 2021 2021 2021 2022 2H CY2
Slide 10: Brain Injury Program
For personal use only Brain Injury Program ASX:NYR NYRADA INC (ASX:NYR) 10 INVESTOR PRESENTATION
Slide 11: Global Market with Large Unmet Need - Brain Injury After TBI or Stroke
Global Market with Large Unmet Need - Brain Injury After TBI or Stroke For personal use only Nyrada is developing a neuroprotectant drug to reduce the impact of secondary brain injury in patients following a stroke or traumatic brain injury (TBI), which can occur following a motor vehicle accident,
Slide 12: Reducing Secondary Brain Injury After TBI or Stroke
Reducing Secondary Brain Injury After TBI or Stroke First-ever drug to improve survivability and patient quality of life For personal use only • Treatment for secondary brain injury following TBI or Stroke • Administered intravenously (TBI and Stroke) or intranasally Primary Secondary Disability Inj
Slide 13: Program Milestones
Program Milestones For personal use only Pilot study Collaboration secured with July evaluating the June CY WRAIR and 2020 intranasal route 2022 UNSW 2021 of delivery for Sydney drug candidates 2H CY2020 CY2021 UPCOMING Feb New, more potent Pilot work to optimise Brain injury drug Phase I first in N
Slide 14: For personal use only
For personal use only Corporate Update ASX:NYR NYRADA INC (ASX:NYR) 14 INVESTOR PRESENTATION
Slide 15: FY2021 Financial Performance Highlights
FY2021 Financial Performance For personal use only Highlights • Nyrada ended FY2021 with cash of $13.8M • Cash position as at 31 December 2021 was $11.1M • R&D Tax Incentive refund of $2.3M relating to the accrued FY2021 refund of $1.3M and received FY2020 refund of $1.0M • R&D Tax Incentive refund
Slide 16: Strong Intellectual Property Position
Strong Intellectual Property Position For personal use only • US Patent granted for Nyrada’s PCSK9 inhibitor technology (expiry date 16 March 2038) • Patent provides composition of matter protection • Corresponding European patent is in the final stages of examination • PCT application filed in Dece
Slide 17: Key Metrics & Timing of Phase I Studies
Key Metrics & Timing of Phase I Studies For personal use only Market capitalisation $29.6M Pathway to Phase I Studies (as at 1 March 2022) Share price $0.19 Expected to Commence* (as at 1 March 2022) CDIs free float 156,008,700 Cholesterol-Lowering Program 2H CY2022 Cash at bank 31 Dec 2021 A$11.1M
Slide 18: Questions?
For personal use only Questions? Brain Injury Solution Cholesterol-Lowering Animation Animation @nyrada_inc @nyrada_inc ASX:NYR info@nyrada.com www.nyrada.com NYRADA INC (ASX:NYR) 18 INVESTOR PRESENTATION
Slide 19: www.nyrada.com
For personal use only www.nyrada.com NYRADA INC (ASX:NYR) 19 INVESTOR PRESENTATION
Nyrada — Meet the CEO, Life Sciences Edition (March 2022) on 6ix